Abstract
Preimplantation genetic screening (PGS) wants to improve artificial reproductive technologies (ART), primarily by raising the rates of pregnancy, implantation and birth. At the moment there are two main approaches for PGS: biopsy of blastocysts, predominantly in the USA, and polar body biopsy, in Europe, both now combined with array comparative genome hybridization (aCGH). Improvement was contested for a long time. And aCGH is expensive when applied to the many oocytes per cycle in comparison to the few blastocysts per cycle.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
